Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of BG136 in Healthy Subjects
NCT05984368Phase 1Unknown
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Aug 2023
- Primary completion
- Sep 2023
- Modality
- Polysaccharide, Biologic, Immune stimulant
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BG136 in solid tumor and colorectal cancer (CRC) (10 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Treatment-related adverse events up to 14 days, Peak Plasma Concentration up to 14 days and 2 more. Status: unknown.
02
Drugs
BG136
03
Conditions
solid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05984368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05984368.